Sanjay Subramanian - 11 Mar 2025 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INZY	Stock Option (right to buy)	Award	$0	+145,000		$0.000000	145,000	11 Mar 2025	Common Stock	145,000	$1.06	Direct	F1, F2
transaction	INZY	Restricted Stock Units	Award	$0	+38,500		$0.000000	38,500	11 Mar 2025	Common Stock	38,500		Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The exercise price represents the closing price of the Issuer's common stock on March 11, 2025.
F2	The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.
F3	The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.